Amphastar Pharmaceuticals Inc (AMPH) Q3 2025 Earnings Call Highlights: Strong Core Product ... [Yahoo! Finance]
Amphastar Pharmaceuticals, Inc. (AMPH)
Last amphastar pharmaceuticals, inc. earnings: 3/12 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amphastar.com/investor-relations
Company Research
Source: Yahoo! Finance
For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points Amphastar Pharmaceuticals Inc ( NASDAQ:AMPH ) achieved net revenues of $191.8 million for the third quarter, with a GAAP net income of $17.3 million. The company's core products, Bexsemi and Primatene Mist, showed strong performance, with Bexsemi sales up 14% year over year and Primatene Mist sales up 11%. Amphastar Pharmaceuticals Inc ( NASDAQ:AMPH ) expanded its proprietary pipeline through an exclusive in-licensing agreement with Nanjing Angi Biotechnology, securing rights to three novel peptide candidates. The company received FDA approval for its iron sucrose injection, AMP 002, which is now commercially available in the United States. Amphastar Pharmaceuticals Inc ( NASDAQ:AMPH ) is on track to launch several high-impact regulatory programs, including AMP 007 inhalation and generic teraparatide product AMP 015, by 2026. Negative Points Glucagon inj
Show less
Read more
Impact Snapshot
Event Time:
AMPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMPH alerts
High impacting Amphastar Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
AMPH
News
- Amphastar Pharmaceuticals (AMPH) Stock Trades Up, Here Is Why [Yahoo! Finance]Yahoo! Finance
- Amphastar Pharmaceuticals (AMPH) Jumps 6.5% After Q3 Beat and Conference Reveal—Has the Investment Case Shifted? [Yahoo! Finance]Yahoo! Finance
- A Look at Amphastar Pharmaceuticals (AMPH) Valuation Following Strong Quarterly Results and Pipeline Progress [Yahoo! Finance]Yahoo! Finance
- Amphastar Pharmaceuticals (NASDAQ:AMPH) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
- Why Amphastar Pharmaceuticals (AMPH) Is Up 8.4% After Strong Q3 Revenue and Key FDA Approvals [Yahoo! Finance]Yahoo! Finance
AMPH
Earnings
- 11/6/25 - Beat
AMPH
Sec Filings
- 11/28/25 - Form 144
- 11/25/25 - Form 4
- 11/25/25 - Form 144
- AMPH's page on the SEC website